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SSX cancer/testis antigens are frequently expressed in melanoma tumors and represent
attractive targets for immunotherapy, but their role in melanoma tumorigenesis has re-
mained elusive. Here, we investigated the cellular effects of SSX2 expression. In A375
melanoma cells, SSX2 expression resulted in an increased DNA content and enlarge-
ment of cell nuclei, suggestive of replication aberrations. The cells further displayed
signs of DNA damage and genomic instability, associated with p53-mediated G1 cell cy-
cle arrest and a late apoptotic response. These results suggest a model wherein SSX2-
mediated replication stress translates into mitotic defects and genomic instability. Ar-
rest of cell growth and induction of DNA double-strand breaks was also observed in
MCF7 breast cancer cells in response to SSX2 expression. Additionally, MCF7 cells
with ectopic SSX2 expression demonstrated typical signs of senescence (i.e. an irregular
and enlarged cell shape, enhanced b-galactosidase activity and DNA double-strand
breaks). Since replication defects, DNA damage and senescence are interconnected
and well-documented effects of oncogene expression, we tested the oncogenic potential
of SSX2. Importantly, knockdown of SSX2 expression in melanoma cell lines demon-
strated that SSX2 supports the growth of melanoma cells. Our results reveal two impor-
tant phenotypes of ectopic SSX2 expression that may drive/support tumorigenesis: First,tigen; DOX, doxycycline; DNA DSB, DNA double-strand break; ICC, immunocytochemistry;
-induced senescence; PRC1, Polycomb Repressive Complex 1; SA-b-gal, senescence-associ-
X chromosome breakpoint.
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M O L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 4 3 7e4 4 9438immediate induction of genomic instability, and second, long-term support of tumor
cell growth.
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reserved.1. Introduction profiling for cell line authentication) and HEK293-Flp-In T-Cancer/testis (CT) antigens represent a group of germ cell-
specific proteinswhose expression is reactivated in tumor cells
(Simpson et al., 2005). Because of the immune-privilegednature
of germ cells, these proteins often elicit humoral and cellular
immune responses in cancer patients (Gjerstorff et al., 2010).
The unique expression pattern and immunogenic properties
of CT antigens make them ideal targets for immunotherapy of
multiple types of human cancer, particularlymelanoma,which
exhibits coordinated expression of CT antigens at high levels
(Barrow et al., 2006; Sahin et al., 1998; Zendman et al., 2001).
Despite their vast therapeutic potential, little is known about
the role of CT antigens in melanoma tumorigenesis, and eluci-
dationof the cellular functionsof theseproteins remains essen-
tial for their further development as therapeutic targets.
The family of Synovial Sarcoma X chromosome breakpoint
(SSX) CT antigens was first identified as part of the chimeric
SS18-SSX fusion protein, which is generated by a transloca-
tion in more than 95% of synovial sarcomas and considered
a main contributor to the development and progression of
this disease (Inagaki et al., 2000). The SSX family comprises
10 highly homologous members frequently expressed in mel-
anoma, but the biological significance of their presence in
melanoma cells has not been evaluated. SSX proteins are
localized in the nucleus and are believed to be transcriptional
repressors. Two repressive domains are found in all SSX fam-
ily members, a Kr€uppel-associated box (KRAB) domain and an
SSX repression domain, the latter being the most potent
repressor in a GAL4-luciferase reporter assay (Brett et al.,
1997; Lim et al., 1998). SSX proteins may also have a role in
regulation of gene expression through modulation of
Polycomb-mediated gene silencing, since SSX1 and SSX2
have been found to co-localize with BMI1 and RING1B of the
Polycomb Repressive Complex 1 (PRC1) in nuclear foci (Barco
et al., 2009; Soulez et al., 1999), and the SSX2 part is essential
for SYT-SSX2-mediated destabilization of BMI1 leading to
reactivation of Polycomb target genes (Soulez et al., 1999).
To elucidate the role of SSX2 in tumorigenesis, we investi-
gated the phenotypic and molecular changes associated with
SSX2 expression in human melanoma and breast cancer cells
and demonstrate that SSX2 possesses oncogenic potential,
further highlighting the potential of this protein as a thera-
peutic target.2. Materials and methods
2.1. Cell lines
A375 and MCF7 cells were obtained from American Type Cul-
ture Collection (ATCC; which uses short tandem repeatREX cells were purchased from Invitrogen, Naerum,
Denmark. All cell lines were kept at a low passage. A375 mel-
anoma cells with tetracycline/doxycycline (TET/DOX)-induc-
ible expression of SSX2 (NM_175698) (A375-TET-SSX2),
CRISP2 (A375-TET-CRISP2) and p21 (CDKN1A) (A375-TET-
p21), and MCF7 cells with TET/DOX-inducible SSX2 expres-
sion (MCF7-TET-SSX2), were generated using a modified
Flp-In system (Invitrogen). Briefly, A375 or MCF7 cells car-
rying a Flp recombinase recognition site were transfected
with the pOG44 plasmid encoding the Flp recombinase and
an expression vector with Flp recombinase recognition site
carrying the genes of interest. Cells with stable integration
of the expression cassette were selected with 300 mg/ml
hygromycin. Three independent clones with similar growth
rates were pooled to avoid undesired effects of clonal selec-
tion. Control A375 or MCF7 cells were generated by integra-
tion of an identical expression vector without an open
reading frame in the same genomic site. Thus, comparing
cells with TET/DOX-induced expression of inserted genes to
uninduced cells and TET/DOX-treated isogenic control cells
accounted for all effects contributed by the elements of the
vector system and TET/DOX treatment. HEK293 cells
(HEK293 Flp-In T-REX, HEK293) with TET/DOX-inducible
expression of SSX2 with an N-terminal 3xFLAG-tag
(HEK293-TET-SSX2-FLAG) were generated with the Flp-In
system (Invitrogen) according to the manufacturer’s
recommendations.
Melanoma cell lines were originally established by Alexei
Kirkin (Kirkin et al., 1998) and kindly donated to our laboratory
by ProfessorMads Hald Andersen, Center for Cancer Immuno-
therapy (CCIT), Herlev Hospital, Denmark. Cells were grown in
DMEM (A375, MCF7, HEK293) or RPMI (FM6, FM45, FM79) sup-
plemented with 10% fetal bovine serum (FBS; Invitrogen),
penicillin (100 U/ml) and streptomycin (100 mg/ml).
Thymidine-mediated G1/S cell cycle arrest of A375 and
MCF7 cells was carried out by adding 2.5 mM of thymidine
to cells for 16 h. Cells were released by removing thymidine
and adding 25 mM of 20-deoxycytidine. After 8 h, MCF7 cells
were subjected to another round of thymidine arrest.
2.2. Lentiviral transfections
Lentiviral particles with SSX2-specific shRNAs were pur-
chased from Santa Cruz Biotech, Heidelberg, Germany (target
sequences: 50-GUA UGA GGC UAU GAC UAA A-30 and 50-GUU
AGC GUU UAC GUU GUA U-30). For lentiviral transfections,
cells were seeded at a density of 20,000 cells/cm2 and the
next day transduced (MOI ¼ 1:5) in media with 5e8 mg/ml of
polybrene. Media was changed after 16 h, and 48 h thereafter
0.1e0.4 mg/ml of puromycin was added to select stable
transfectants.
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For CellTiter blue viability assays (Promega, San Luis Obispo,
CA, USA), cells were seeded in 96-well plates at a density of
4.7  103 cells/cm2. After 24 h media was changed to include
DOX in indicated concentrations. At indicated times, cells
were stained with CellTiter-Blue diluted in phenol red-free
MEM (Invitrogen) (1:5) andmeasured at 560/590 nm. For clono-
genic assays, cells were seeded in 6- or 12-well plates
(50e100 cells/cm2) in standard media with different concen-
trations of DOX (where relevant). After 10e14 days, cells
were stained with 0.5% crystal violet in 25% methanol. For
cell cycle analysis, cells were harvested by trypsinization,
fixed in 84% ethanol and incubated at 37 C for 30 min in fresh
propidium iodide/RNase solution (0.05 mg/ml propidium io-
dide, 3.8 mM sodium citrate, 10 mM TriseHCl (pH 7.5), 5 mM
MgCl2, 0.1 mg/ml RNaseA) at a density of 1  106 cells/ml pro-
pidium iodide/RNase solution. To arrest cells inmitosis before
cell cycle analysis, 0.25 mM paclitaxel (SigmaeAldrich,
Brondby, Denmark) diluted in ethanol or 200 nM nocodazole
(SigmaeAldrich) in dimethyl sulfoxide was added. Staining
of apoptotic cells was carried out with the Vybrant Apoptosis
Assay Kit 2 (V13241; Invitrogen) essentially as specified by the
manufacturer. The level of SA-b-galactosidase activity in cells
was measured using the Senescence Detection Kit according
to the manufacturers recommendations (BioVision, Milpitas,
CA, USA).
2.4. Tumorigenicity in SCID mice
Female immunodeficient CB17 SCID mice (Taconic, Ry,
Denmark) were maintained in pathogen-free conditions
with access to water and food ad libitum. Groups of seven
mice were injected subcutaneously in the flanks with either
106 A375-TET-SSX2 cells or 106 control A375 cells in DMEM
mixed with Matrigel in a total volume of 50 ml. DOX was
administered to both groups of mice in drinking water at a
concentration of 200 mg/ml. All animal experiments were per-
formed at the Biomedical Laboratory, University of Southern
Denmark and approved by The Experimental Animal Commit-
tee, The Danish Ministry of Justice.
2.5. Quantitative RT-PCR
Total RNA was purified using Trizol (Invitrogen) for tumor
samples or the RNeasy Mini Kit from Qiagen, Copenhagen,
Denmark, for cell culture samples. A RevertAid Premium
Reverse Transcriptase kit (Fermentas, Slangerup, Denmark)
was used for cDNA synthesis. Relative quantification of gene
expression was performed with SYBR green PCR Mastermix
(Applied Biosystems, Naerum, Denmark). Primers for SSX2,
GAPDH and PUM1were purchased from Qiagen. The “TissueS-
can RT Melanoma panel I” with cDNA from three healthy and
40 melanoma samples was purchased from OriGene, Rock-
ville, MD, USA.
2.6. Immunostaining
Methods for Western blotting, immunocyto- and immunohis-
tochemistry were described previously (Gjerstorff et al., 2006;Greve et al., 2014). The use of clinical specimenswas approved
by the ethical committee of Funen and Vejle County
(VF20050069).2.7. Antibodies
Anti-panSSX (1:50 for Western blotting, sc-28697), anti-SSX2/
SSX3 (mAb 1A4, which has been demonstrated to recognize
SSX2 and SSX3, but not SSX1, SSX4 or SSX5 (Smith et al.,
2011); 1:700 for immunohistochemistry (IHC) and 1:200 for
immunocytochemistry (ICC);, Novus Biologicals, Cambridge,
UK), anti-cyclin A (1:200 for Western blotting, sc-596, Santa
Cruz), anti-SSX2-4 (mAb E3AS (dos Santos et al., 2000), 1:3000
for Western blotting), anti-cyclin B1 (1:2000 for Western blot-
ting, sc-245, Santa Cruz), anti-cyclin D1 (1:2000 for Western
blotting, sc-718, Santa Cruz), anti-cyclin E (1:200 for Western
blotting, sc-247, Santa Cruz), anti-p21 (1:100 for Western blot-
ting, clone SX118, Dako, Glostrup, Denmark), anti-p53 (1:1000
for Western blotting, MCA1703, AbD Serotec, Dusseldorf, Ger-
many), anti-Ki67 (1:300 for ICC, ab15580, Abcam, Oxford, UK),
anti-a-/b-tubulin (1:50 for ICC, #2148, Cell Signaling, Danvers,
USA), anti-g-H2AX (1:2000 for ICC, ab22551, Abcam), anti-g-
H2AX 20E3 (1:50 for fluorescence IHC; #9718, Cell Signaling),
anti-g-H2AX (1:50 for flow cytometry; clone 20E3, Cell
Signaling), anti-CDK1 (predicted to also react with
CDK2/CDK3) (1:1000 for Western blotting; #9112, Cell
Signaling), anti-P-CDK1-/CDK2/CDK5-Y15 (predicted to also
react with P-CDK3-Y15) (1:1000 for Western blotting; #9111,
Cell Signaling), anti-P-CHK1-S317 (1:1000 forWestern blotting;
#12302, Cell Signaling), anti-P-CHK1-S345 (1:1000 for Western
blotting; #2341, Cell Signaling).2.8. Confocal microscopy
AnOlympus FluoView FV1000MPE confocal laser scanningmi-
croscope fitted with an Olympus objective (XLUMPLFL20xW,
20, NA:0.95) was used at room temperature. Images were ac-
quired sequentially with 405 nm, 488 nm and 559 nm lasers
and the corresponding 400e450 nm, 477.5e522.5 nm and
575e675 nm band-pass filters, respectively. Image acquisition
of z-stacks covering the entire cell layer depth (1 mm steps,
3 zoom) and 3D conversion was carried out with FluoView
(FV-ASW 2.1) software (Olympus, Hamburg, Germany). Three
random ‘stacks’ per specimen were acquired and the number
of Ki67-positive cells and gH2AX foci per cell quantified using
ImageJ software.2.9. p53 reporter assay
Melanoma cell lines were stably transducedwith lentiviral par-
ticles carrying the pGreenfire-p53 GFP reporter plasmid (Sys-
tem Biosciences, Mountain View, CA, USA). In brief, HEK293T
cells were co-transfected with pGreenfire-p53 and packaging
plasmids pVSVG, pRSV-Rev and pMDL g/p RRE (plasmids
were kindly provided by the Tronolab through Addgene, Cam-
bridge, MA, USA) and, after 72 h, supernatant containing virus
was harvested and transferred to target cells. Seventy-two
hours after transduction, cells were selected with puromycin
for 7 days. The GFP signal in cells treated for 16 h with 50 mM
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cytometer (BD, Albertslund, Denmark).
2.10. Statistics
The non-parametric MannWhitney test was chosen in the ex-
periments involving the number of gH2AX foci where
normality cannot be assumed. Student’s t-test was used in
all other experiments.
2.11. EdU/BrdU flow cytometry assays
A375-TET-SSX2 or MCF7-TET-SSX2 cells were treated with
50 ng/ml DOX starting 24 h before release from G1/S arrest,
or left untreated. Upon release, cells were pulsed with EdU
or BrdU for 60 min and harvested at indicated times. EdU or
BrdU staining was carried out according to the recommenda-
tions of themanufacturers (EdU, EdU flow cytometry assay kit,
Life Technologies; BrdU, APC BrdU flow kit, BD Biosciences).
2.12. Cytometric assessment of g-H2AX
Cells were harvested, fixed in ice-cold 70% ethanol for at least
2 h at 20 C and permeabilized with PBS, 1% BSA, 0.2% Triton
X-100 (T-BSA-PBS). After two 5-min washes in T-BSA-PBS,
cells were incubated with Alexa Flour 488-conjugated anti-g-
H2AX in T-BSA-PBS overnight at 4 C in the dark. The cells
were then washed and stained with 0.5 ml DNA staining solu-
tion [PBS, 0.5 ml FxCycle Far Red Stain (F10348, Life Technol-
ogies), 50 mg RNase (R4642, Sigma)] for 30min in the dark. Flow
cytometry analysis was performed on an LSRII flow cytometer
(BD Biosciences). The procedure was modified from (Huang
and Darzynkiewicz, 2006).3. Results
3.1. SSX2 expression reduces cell viability and
clonogenicity
To investigate the role of SSX2 in cancer cells, we generated an
A375 melanoma cell line with TET/DOX-inducible SSX2
expression (A375-TET-SSX2) (Figure 1A) and an isogenic con-
trol cell line carrying an identical expression vector, but
without the SSX2 open reading frame (termed A375). To vali-
date the in vivo relevance of this cell model, we compared
the DOX-induced SSX2 expression level (A375-TET-SSX2
þDOX) with the level observed in tumors frommelanoma pa-
tients (Supplementary Figure 1). SSX-expression has previ-
ously been demonstrated in about 30% of melanomas (dos
Santos et al., 2000). mRNA from 40 randomly selected mela-
nomas were evaluated for SSX2 expression by quantitative
PCR, and 4 of these (10%) exhibited a higher expression level
of SSX2 than DOX-treated (50 ng/ml) A375-TET-SSX2 cells,
demonstrating that our experimental conditions reflected
the clinical cancer setting.
Surprisingly, viability assays and growth curves showed
that the SSX2-expressing A375 cells stopped expansion after
48 h and exhibited a 47% (p < 105) reduction in cell viability
(Figure 1B, C and Supplementary Figure 2). Using increasingamounts of DOX (0.1e50 ng/ml), we gradually increased the
level of SSX2 protein induced, causing a dose-dependent
reduction in viability and clonogenicity (Figure 1DeF). Using
similar TET/DOX-regulated isogenic expression systems,
SSX2 was also demonstrated to reduce the clonogenicity of
MCF7 breast cancer cells (MCF-TET-SSX2) and HEK293 human
embryonic kidney cells (HEK293-TET-SSX2) (Figure 1E, F),
establishing that the effect was not restricted to cells of the
melanocyte lineage. The reduced growth of SSX2-expressing
A375 melanoma cells was confirmed by reduction in EdU
incorporation (Figure 1G) and in vivo growth studies exam-
ining the tumor-forming capacity of A375-TET-SSX2 cells in
immunodeficient mice (Supplementary Figure 3). Ten of 14
mice injected with control A375 melanoma cells developed
large tumors, while none of the mice injected with A375-
TET-SSX2 cells developed tumors over a period of 21 days.
3.2. SSX2 expression induces G1 checkpoint arrest in
A375 cells
The growth-inhibitory effects of SSX2 were most dramatic in
A375-TET-SSX2 cells, and the nature of this response was
investigated further. Analysis of cell cycle phase distribution
after paclitaxel (Figure 2A) or nocodazole (Supplementary
Figure 4) treatment to arrest cells in M-phase suggested that
A375-TET-SSX2 cells, after 24e48 h of SSX2 expression,
exhibited either a partial G1 arrest or a bypass of the induced
M-phase arrest. The latter was ruled out by EdU incorporation
in combination with paclitaxel-induced M-phase arrest and
measurement of cells reentering G1 upon release, as SSX2
did not increase the number of cells reentering G1
(Figure 2B). To evaluate a possible G1 arrest, we synchronized
cells in G1/S and EdU labeled them upon release and assessed
cell cycle kinetics in cells with andwithout SSX2. This demon-
strated that cells passed through the S- and M-phases and
reentered G1 at a similar rate independent of SSX2 expression.
However, SSX2 induced a three-fold increase in the number of
cells stuck after reentering G1, confirming a partial G1 arrest
(Figure 2C).
Quantification of cell cycle regulators by Western blotting
supported the above results (Figure 2D), as SSX2 expressing
cells exhibited reduced levels of cyclin A and B, while accumu-
lating cyclin E and D. Furthermore, SSX2 induced a clear
reduction in the total level of cyclin dependent kinases
(CDK1, CDK2, CDK3) and, importantly, also the active Y15-
phosphorylated form, supporting cell cycle arrest. A key regu-
lator of the G1/S checkpoint is the p53-p21-RB pathway and, in
agreement with this, we found increased levels of both p53
and p21. Annexin V and propidium iodide staining demon-
strated an increased percentage of apoptotic and dead cells af-
ter 48e96 h of SSX2 expression (Figure 2E), which may be a
direct result of p53 activation. In total, these results clearly
indicate that SSX2 expression induces a p53-p21emediated
G1 arrest in A375 cells, followed by an apoptotic response.
3.3. SSX2 expression causes replication defects and
genomic instability in A375 melanoma cells
Cell cycle analysis of A375-TET-SSX2 cells after 4e6 days of
SSX2 expression revealed a broadening and a right-shift of
Figure 1 e Ectopic SSX2 expression inhibits cell growth. (A) Quantitative PCR and Western blot analysis of SSX2 expression in A375-TET-SSX2
melanoma cells with DOX-inducible SSX2 expression (A375-SSX2) and control A375 cells. (B) Cell density of A375-TET-SSX2 cells after 96 h with
or without DOX-induction of SSX2. (C) CellTiter-Blue assay examining the number of living (metabolic active) A375 cells after 96 h with DOX-
induced expression of SSX2, the cancer/testis antigen CRISP2 (negative control) or p21 (positive control). (D) CellTiter-Blue viability assay (top
panel, bars depict growth reduction in % compared to sample without DOX) and Western blot analysis (lower panel) of SSX2 protein levels in cells
induced with increasing amounts of DOX for 48 h. (E) Western blot analysis of SSX2 expression in MCF7 and HEK293 cells with TET/DOX-
inducible SSX2 expression (MCF7-SSX2 and HEK293-SSX2) and control MCF7 and HEK293 cells. (F) Clonogenicity of A375-TET-SSX2,
MCF7-TET-SSX2 and HEK293-TET-SSX2-FLAG cells with or without SSX2 expression, relative to DOX treated controls (no SSX2 insert). Cells
were stained with crystal violet after 10e14 days of growth. (G) The percentage of cycling cells was measured by EdU incorporation in A375-TET-
SSX2 and MCF7-TET-SSX2 cells with or without SSX2 expression. Cells were DOX-treated for 24 h for induction of SSX2 expression and pulsed
with EdU for additional 24 h. Average of duplicates are shown. The DOX concentration used in AeC, E and G was 50 ng/ml.
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crease in DNA content, which suggested induction of genomic
instability in the cells. Therefore, we evaluated the level of
DNA damage (DNA double-strand breaks (DSBs), measured
as the number of g-H2AX foci) in A375-TET-SSX2 cells with
andwithout inducedSSX2expression (Figure 3B). Ki67 staining
was included to distinguish proliferating from arrested cells.Indeed, we observed an overall increase in g-H2AX foci after
48 h of SSX2 induction, with g-H2AX foci present in 78% of
the A375-TET-SSX2 þDOX cells (2.48 foci/cell) vs. 42% in
A375-TET-SSX2 cells (0.52 foci/cell) (Figure 3C, D). After 72 h,
the number of cells with a high amount of foci (>8) had
increased considerably from 2 to 12% of A375-TET-SSX2
þDOX cells compared to an increase from 2 to 3% in A375-
Figure 2 e SSX2 induces G1 checkpoint arrest and apoptosis in A375 melanoma cells. (A) Cell cycle analysis of A375-TET-SSX2 cells after
paclitaxel treatment. Paclitaxel was added either 24 or 48 h after DOX induction of SSX2 and cells harvested after 0, 6 and 24 h of paclitaxel
treatment. (B) Cell cycle kinetics. A375-TET-SSX2 cells with or without DOX-induced SSX2 expression were treated with paclitaxel for spindle
checkpoint activation and the number of cells reentering G1 was quantified by flow cytometry after release. Average of duplicates are shown. (C)
Cell cycle kinetics. A375-TET-SSX2 cells, with or without DOX-induced SSX2 expression, released from thymidine induced G1/S arrest, were
EdU-labeled and cells reentering G1 was quantified by flow cytometry. Average of duplicates are shown. (D) Western blot analysis of relevant cell
cycle regulators in A375-TET-SSX2 cells with or without DOX-induced SSX2 expression. (E) Apoptosis and dead cell analysis with Annexin V
and propidium iodide. Each plot shows accumulated data from 3 independent samples, % ± standard deviation. *DDOX significantly differently
from LDOX (p £ 0.01). The DOX concentration used in AeE was 50 ng/ml.
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decreased number of proliferating SSX2-expressing cells seen
in the other assays (Figure 3E) and also showed an inverse cor-
relation between g-H2AX and Ki67 staining, suggesting that
DNA damage was causative for decreased proliferation
(Figure 3B, arrows). The frequency of Ki67-positive cells wasalso reduced inA375-TET-SSX2 control cells at day 3 compared
to day 2, but this was due to overgrowth of these cells. DOX
treatment alone did not affect Ki67 status or g-H2AX staining
in A375 control cells (Supplementary Figure 5).
Interestingly, many SSX2-expressing A375-TET-SSX2
cells had enlarged nuclei (Figure 3B), which can be a
Figure 3 e SSX2 causes genomic instability in A375 melanoma cells. (A) Cell cycle analysis showing increased DNA content in A375-TET-SSX2
cells with SSX2 expression. Arrows indicate the upper limit of the G2 populations. Dot plot of DNA signal width vs. area for A375-TET-SSX2 cells
to test for cell aggregates. (BeF) A375-TET-SSX2 cells were grown for 48e72 h with or without 50 ng/ml DOX for SSX2 expression, fixed and
stained with DAPI for nuclei visualization (blue), the proliferation marker Ki67 (Alexa-568, red) and g-H2AX for identification of DNA double-
strand breaks (FITC, green). (B) Representative pictures. (CeF) Quantification of confocal images from 3 individual frames (day 2, n[ 197; day 3,
n[ 206): (C) g-H2AX foci/cell were quantified in ImageJ and each cell assigned to groups with 0, 1e3, 4e7, 8e10 and>10 foci/cell, respectively.
(D) Average number of g-H2AX foci/cell. MannWhitney test: **, p[ 0.0038; ****p< 0.0001. (E) Percentage of Ki67-positive cells. (F) Percentage
of cells with micronuclei. (G) SSX2-expressing cell with two g-H2AX-positive chromosome fragments. (H) SSX2-expressing cells with anaphase
bridges and an SXX2-negative cell without anaphase bridges. Dotted lines mark the boundaries of the nuclei. (I) Flow cytometric analysis of g-
H2AX/DNA stained A375-TET-SSX2 cells with or without 48 h of DOX-induced SSX2 expression. The DOX concentration used in AeI was
50 ng/ml. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
MO L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 4 3 7e4 4 9 443consequence of replication defects and inability to complete
DNA synthesis (Shimizu et al., 2013; Zhu et al., 2004), thus
indicating replication defects as a result of SSX2 expression.
Therefore, we investigated the level of CHK1 phosphoryla-
tion at Ser317 and Ser345, which is mediated by the ATRkinase in response to replication defects/stress (Ward
et al., 2004; Zhao and Piwnica-Worms, 2001), but found no
evidence of increased phosphorylation in association with
SSX2 expression (Supplementary Figure 6). A high level of
background CHK1 phosphorylation on Ser345 was observed
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perturbed.
Notably, SSX2 expression resulted in a dramatic increase in
the formation of micronuclei and nuclear blebs (Figure 3B, F),
which are signs of ongoing genomic instability and can be
caused by, for instance, replication and/or mitotic defects (Xu
et al., 2011; Yasui et al., 2010). Most of the observed micronuclei
showedDNADSBs (Figure3B, arrowheads), asdidsomechromo-
some fragments in metaphase cells (Figure 3G, arrowheads).
Micronuclei comprisingDNADSBshave specificallybeenassoci-
ated with replication stress (Xu et al., 2011). Anaphase bridges
werealsoobserved inA375-TET-SSX2cellswithSSX2expression
(Figure 3H), but the mitotic spindle apparatus appeared normal
(Supplementary Figure 7). Cell cycle analysis in combination
with g-H2AX staining demonstrated DNA DSBs in cells in all
phases of the cell cycle, however, the majority of g-H2AX-posi-
tive cells were in G1 after 48 h of SSX2 expression (Figure 3I).
In conclusion, our results suggest that SSX2 causes replica-
tion defects in A375 melanoma cells leading to anaphase
bridges, genomic instability and as a result a p53-p21-
mediated G1/S checkpoint arrest.
3.4. SSX2 expression in melanoma cells is independent
of p53 status
Induction of p53 and p21 in A375 cells in response to SSX2 sug-
gested that this pathway was essential for the observed G1 ar-
rest and apoptotic response. In agreement, knockdown of
TP53 expression in A375-TET-SSX2 cells using lentiviral deliv-
ery of siRNAs (Figure 4A) increased the clonogenicity of A375-
TET-SSX2 cells with induced SSX2 expression (Figure 4B, C).
This suggested that an impaired p53 response might be a pre-
requisite for tolerance of prolonged SSX2 expression in mela-
noma cells. To clarify this, we investigated the p53 response in
a panel of SSX2-positive and -negative melanoma cell lines
using a p53 response element reporter assay (Figure 4D,E).
The assay demonstrated a defective p53 response in one
SSX2-positive cell line (FM79), while two other SSX2-positive
cells lines (FM45 and FM6) showed functional p53 responses.
This result suggested that SSX2 expression in melanoma cells
is not dependent on p53 status, but may also reflect unidenti-
fied perturbations of p53 downstream effector molecules (e.g.
p21 or RB) in SSX2-positive cell lines, as exemplified by high
viability and growth of FM6 cells with relatively high endoge-
nous levels of p53 activity (Figure 4D,E).
3.5. SSX2 expression induces a senescence-like
phenotype in MCF7 breast cancer cells
Similar to A375-TET-SSX2 cells, MCF7-TET-SSX2 cells exhibited
reduced proliferation in response to SSX2 expression
(Figure 1E,F), whichwas also corroborated by changes in cell cy-
cle regulators (e.i. cyclin A and B1, p53, p21 and cyclin-
dependent kinases; Figure 5A) and an increased percentage of
cells in G1 phase (Figure 5B). Long-term growth (more than
7 days) of MCF7-TET-SSX2 cells with SSX2 expression induced
a dramatic change in themorphology of the cells, which adapt-
ed an irregular and enlarged shape (Figure 5C). Similar changes
were observed upon induction of SSX2 expression in HEK293-
TET-SSX2 cells and surviving A375-TET-SSX2 cells, but to alesser extent (Figure 5C). An irregular and enlarged cellular
morphology is typical for cells that undergo a senescence
response, which is an irreversible arrest of growth that can
be induced by different types of stress, including oncogene
expression (Rodier and Campisi, 2011). To further investigate
if the SSX2-expressing cells were senescent, we assayed their
senescence-associated b-galactosidase (SA-b-gal) activity.
MCF7-TET-SSX2 cultures with DOX-induced expression of
SSX2 exhibited increased SA-b-gal activity in aminority of cells
after three days, and in the majority of cells after six days
(Figure 5D). Increased SA-b-gal activity was also observed in
some of the few surviving A375-TET-SSX2 cells, but not until
six days of SSX2 expression. HEK293-TET-SSX2 cells exhibited
very high background levels of SA-b-gal activity, and no differ-
ence was observed upon induction of SSX2 expression
(Figure 5D). Immunocytochemical analysis of MCF7-TET-SSX2
cells 7 days after induction of SSX2 expression further substan-
tiated their senescent phenotype, as they exhibited a clear
reduction in expression of the proliferation marker Ki67 and
presence of g-H2AX DSB foci (Figure 5E).
3.6. Knockdown of SSX2 expression diminishes the
growth of melanoma cells
As replication defects, genomic instability and senescence are
common effects of acute oncogene expression we investigated
the role of SSX2 in sustaining growth of melanoma cell lines in
order to explore the oncogenic potential of SSX2. SSX2 expres-
sion was knocked down in three melanoma cell lines exhibit-
ing endogenous SSX2 expression (i.e. FM6, FM45 and FM79)
using stable lentiviral transduction (Figure 6A, B). This consid-
erably reduced the cell number of FM45 and FM79 cells 3 and 6
days after seeding, while FM6 showed a slight increase in cell
number (Figure 6C). This was corroborated by clonogenic as-
says, which demonstrated reduced clone-forming capacity of
FM45 and FM79 cells, and slightly increased clone-forming ca-
pacity of FM6 cells, upon SSX2 knockdown (Figure 6D). To
determine if the observed SSX2-mediated decrease in clonoge-
nicity of FM45 and FM79 cells was caused by an increase in the
level of cell death, we performed anAnnexin V apoptosis assay
(Supplementary Figure 8) and found no SSX2-related effects on
the apoptotic rate of these melanoma cell lines. In total, these
experiments demonstrated a context-dependent capacity of
SSX2 to support the growth of melanoma cells.4. Discussion
Despite the great potential of CT antigens as targets for can-
cer treatment, their role in melanoma, and cancer develop-
ment in general, remains elusive. In this study, we
investigated the phenotypic effects of SSX2 CT antigen
expression and now provide the first clues to its role in tumor
development.
Induced SSX2 expression was initially found to have a
strong inhibitory effect on the growth of various cell types
(i.e. melanoma, breast and kidney). This wasmost pronounced
in A375 melanoma cells, where ectopic SSX2 expression was
demonstrated to induce DNA DSBs and genomic instability,
with clear signs of replication defects, including formation of
Figure 4 e Knockdown of TP53 expression rescues A375 cells from SSX2-mediated growth arrest. (A) A375-TET-SSX2 cells were stably
transfected with TP53 or control scrambled shRNAs and p53 knockdown was confirmed by Western blotting. (B) The clonogenicity of A375-
TET-SSX2 cells carrying the TP53 or scrambled shRNA was tested by seeding 100 cells/cm2 in media with increasing concentrations of DOX to
induce increasing levels of SSX2 expression. Clones were stained with crystal violet after 10 days. (C) The relative clonogenicity (# of clones) of
A375-TET-SSX2 cells carrying the TP53 or scrambled shRNA with different levels of SSX2 expression (different samples than in B) compared to
cells without induction of SSX2 (error lines represent standard deviation of triplicates). (D) The SSX2 status of a panel of melanoma cell lines was
assessed by Western blotting using anti-SSX2-4 (Mab E3AS). (E) Melanoma cell lines were stably transfected with a plasmid carrying a GFP
reporter gene under the transcriptional control of a p53 response element. The basic and induced (with etoposide (50 mM); Eto) p53 activity was
assayed by flow cytometry. SSX2 status (D/L) is indicated in brackets.
MO L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 4 3 7e4 4 9 445large nuclei and increased DNA content. This led to activation
of the p53-p21 pathway and G1-checkpoint arrest after
24e48 h, and subsequently apoptosis after 4 days. The effect
of SSX2 expression in MCF7 cells was delayed compared to
A375, and here SSX2 induced a senescent-like phenotype (i.e.
enlarged cell size, b-galactosidase expression, loss of Ki67,
DNA DSBs and activation of the p53-p21 pathway) within 7
days. In contrast to A375, induction of p53 and p21 was not
found until 3 days of SSX2 expression, and we detected no
DNA DSB foci in MCF7 cells before 7 days of SSX2 induction
(e.g. no g-H2AX foci after 48 h Supplementary Figure 9).From these results, we conclude that ectopic expression of
SSX2 induces DNA DSBs and activation of the p53-p21
pathway in different types of cells, but the overall outcome
varies (genomic instability vs. senescence). The likely expla-
nation for the deviating phenotype of SSX2 expression in
A375 cells compared to MCF7 cells is that the DNA damage
associated with SSX2-induced replication stress can result in
genomic instability if DNA repair and/or checkpoint mecha-
nisms are perturbed (e.g. in A375 cells). In contrast, themolec-
ular landscape of, for example, MCF7 cells may allow
maintenance of genomic integrity upon SSX2 expression and
Figure 5 e SSX2 induces a senescence-like phenotype in MCF7 breast cancer cells. (A) Western blot analysis of relevant cell cycle regulators in
MCF7-TET-SSX2 cells with or without DOX-induced SSX2 expression. (B) Flow cytometric analysis of DNA content (Far Red Stain) shows an
increase in the relative number of cells in G1 phase (48 h) in SSX2-expressing MCF7-TET-SSX2 cells. (C) Long-term growth of MCF7-TET-
SSX2, A375-TET-SSX2 and HEK293-TET-SSX2 (H293-TET-SSX2) cells with SSX2 expression (10e14 days) induced an irregular and enlarged
cells shape. DOX concentrations (induction of SSX2) are indicated. (D) Assay to detect senescence-associated b-galactosidase activity as
represented by the ability of the cells to hydrolyze X-gal and produce blue coloration. Cells were cultured for 3 or 6 days after induction of SSX2
expression before conducting the assay. (E) Immunocytochemical analysis of Ki67 and g-H2AX in MCF7 cells 7 days after induction of SSX2
expression. The DOX concentration used in A, B, D and E was 50 ng/ml.
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bility, checkpoint activation and apoptosis. A higher ability
to maintain genomic integrity in MCF7 cells, compared to
A375 cells, was supported by a much higher background level
of DNA DSBs in the latter.Interestingly, it has recently been demonstrated that repli-
cation stress plays an essential role in causing genomic insta-
bility in tumors, through generation of structural
chromosomal abnormalities that translate into chromosome
missegregation (Burrell et al., 2013). This closely resembles
Figure 6 e SSX2 supports the growth of melanoma cells. (A) Immunohistochemical staining of melanoma cell lines with endogenous SSX2/3
expression (FM6, FM45 and FM79) with anti-SSX2/3 mAb 1A4. (B) The melanoma cell lines were transduced with lentivirus carrying SSX2-
specific shRNAs or scrambled control shRNA and knockdown verified by Western blotting (anti-SSX2-4, mAb E3AS). (C) Cells carrying SSX2-
specific or scrambled shRNAs was seeded at equal densities and the number of cells was counted after 3 and 6 days. Error bars show standard
deviation of triplicates. (D) Clonogenicity of cells carrying SSX2-specific or scrambled shRNA. Triplicates were stained with crystal violet after
10e14 days of growth.
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suggests that de novo SSX2 expression in tumorsmay promote
genomic instability through replication stress.
Within the last few years, it has become evident that
cellular senescence can occur in response to oncogene expres-
sion in premalignant and malignant lesions as an important
barrier to tumorigenesis (Bartek et al., 2007; Bartkova et al.,
2006; Dhomen et al., 2009; Halazonetis et al., 2008; Serrano
et al., 1997). Phenotypes associated with oncogene-induced
senescence (OIS) include increased DNA damage and genomic
instability as a result of replication stress (Bartek et al., 2007;
Di Micco et al., 2006; Halazonetis et al., 2008; Suram et al.,
2012). Since the phenotypes associated with SSX2 resemble
those of OIS, we investigated the effect of knockdown of
endogenous SSX2 on the growth and clonogenicity of mela-
noma cells. This demonstrated that SSX2 supports the growth
of FM45 and FM79 cells, further substantiating the role of SSX2
as an oncogene in melanoma.
SSX proteins are normally expressed at the spermatogonial
stage of spermatogenesis (dos Santos et al., 2000). Spermato-
gonia have many similarities to cancer cells, including the
ability to self-renew and proliferate, and SSX2 may be
involved in defining these phenotypes in both spermatogonia
and cancer cells (Simpson et al., 2005). Interestingly, SSX2
knockdown slightly promoted the growth and clonogenicityof FM6 cells, suggesting that the role of SSX2 in supporting
melanoma growth is context-dependent and highlighting
the need for further characterization of cooperating factors
to enable selection of patients with SSX2-positive tumors
who might benefit from SSX2-targeted therapy.
In conclusion, our results show that SSX2 may directly
contribute to important phenotypes of cancer development
(i.e. genomic instability and support of unlimited growth).
This proposes SSX2 as a candidate oncogene and highlights
its potential utility asa target for treatmentof thisdisease, since
the best targets are believed to support the cancer phenotypes.
However, additional functional characterization is needed
before the therapeutic value of SSX2 undergoes clinical trials.Acknowledgments
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